Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Radcliffe Department of Medicine's Professor Shoumo Bhattacharya has been working with a UK-based biotechnology firm to find out if his research on the ‘pharmacological goldmine’ in tick saliva might offer a treatment option for COVID-10 patients.

Close up photo of adult female deer tick crawling on a piece of straw

Professor Bhattacharya’s work has found that tick saliva could potentially yield many new drugs which could treat disorders ranging from cardiovascular diseases and stroke to arthritis. His research group has identified a group of tick saliva proteins called evasins, which bind to and neutralise chemokines, a group of chemicals key to causing inflammation in the body.

The researchers also worked out the structural trick that enables tick evasins to block a complex pathway that has multiple routes to the same response. What’s more, they can manipulate this structure to make new, custom-made proteins, producing developed triple headed evasins – essentially combining three different types of evasins to maximise the absorption of chemokine messengers responsible for inflammation in the lungs and circulatory system.

Read more on the Radcliffe Department of Medicine website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.